---
document_datetime: 2025-01-27 14:24:43
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ozempic-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ozempic-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.2898789
conversion_datetime: 2025-12-29 22:20:14.389093
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ozempic

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                               |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0046              | Please refer to the Recommendations section C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 12/12/2024                          |                                             | SmPC and PL                      | In the kidney outcomes trial FLOW, semaglutide was superior to placebo, in addition to standard-of-care, in preventing the primary composite outcome of persistent ≥50% reduction in eGFR, onset of persistent eGFR <15 ml/min/1.73 m2, initiation of chronic kidney replacement therapy, kidney death or cardiovascular death with a |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | hazard ratio of 0.76 [0.66; 0.88]95% CI, corresponding to a relative risk reduction in kidney disease progression of 24%. The individual components of the primary composite contributed to the treatment effect but there were few kidney deaths. Semaglutide showed superiority over placebo, in addition to standard-of-care, in reducing the yearly rate of change in eGFR with an estimated treatment difference of 1.16 (ml/min/1.73m2/year) [0.86; 1.47]95% CI. Treatment with semaglutide improved overall survival with a significant reduction in all-cause mortality. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1792   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                       | 14/10/2024 |            | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0049/G | This was an application for a group of variations. B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol B.II.z - Quality change - Finished product - Other variation | 11/10/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0047   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                          | 30/08/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| X/0043    | Annex I_1.(c) Replacement of a biological AS with                                                                                                                                                                                                                                                                                                                    | 25/04/2024 | 10/06/2024 |             | Please refer to the scientific discussion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | one of a slightly different molecular structure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        | EMEA/H/C/004174/X0043                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044/G           | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products | 25/04/2024 | 10/06/2024 | SmPC, Labelling and PL | SmPC Sections 2, 6.5 and 8 are being updated to include a new 0.5 mg pen variant of 0.68 mg/ml in a 3 ml cartridge (glass) in pre-filled pen (FlexTouch) for the sterile parenteral biological medicinal product Ozempic, 0.5 mg solution for injection 1 pen + 4 needles (EU/1/17/1251/012) and add a new 3 pens + 12 needles presentation of 0.5 mg pen variant of 0.68 mg/ml in a 3 ml cartridge (glass) in pre-filled pen (FlexTouch) for the sterile parenteral biological medicinal product Ozempic, 0.5 mg solution for i njection (EU/1/17/1251/013). The labelling and Package Leaflet are updated accordingly. |
| PSUSA/10671 /202305 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/01/2024 | 21/03/2024 | SmPC, Annex II and PL  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10671/202305.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0045             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 07/03/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0041             | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18/10/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | without process change (e.g. of line)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | increased/decreased duplication   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/2541   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                              | 31/08/2023 | n/a |                                   |
| WS/2494/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.z - Quality change - Active substance - Other | 31/08/2023 | n/a | variation                         |
| IB/0038/G | This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/04/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product   |            |            |             |                                                                                                                                                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10671 /202205 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                 | 26/01/2023 | 31/03/2023 | SmPC and PL | Please refer to semaglutide PSUSA/10671/202205 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IB/0037/G           | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   | 21/02/2023 | n/a        |             |                                                                                                                                                                |
| IB/0036/G           | This was an application for a group of variations. B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol B.II.z - Quality change - Finished product - Other variation                                                                    | 24/11/2022 | n/a        |             |                                                                                                                                                                |
| WS/2343             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                             | 20/10/2022 | n/a        |             |                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                          |            |            |                                  |                                                                                                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0035             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                           | 19/10/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| R/0030              | Renewal of the marketing authorisation.                                                                                                                                                | 21/07/2022 | 21/09/2022 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ozempic in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0034             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                   | 08/09/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IB/0031             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                           | 15/07/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| PSUSA/10671 /202111 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                              | 07/07/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IB/0029/G           | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.a - Replacement or addition of a | 24/06/2022 | 21/09/2022 | Annex II and PL                  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2141 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the Ozempic SmPC in order to include information on the use of semaglutide s.c. once weekly vs insulin aspart three times daily, both as add-on to metformin and optimised insulin glargine U100 treatment in subjects with inadequately controlled T2DM; based on the final report from study NN9535 -4386 (SUSTAIN-11), listed as a category 3 study in the RMP. This is a 52 - week, multi-centre, multinational, open-label, active controlled, two armed, parallel, randomised trial undertaken to investigate the effect on glycaemic control, body weight, safety and health-related quality of life. The SmPC of Rybelsus (semaglutide p.o.) is not impacted. The RMP common for both products has also been updated to version 7.1. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 07/04/2022 | 21/09/2022 | SmPC | In a 52 -week open-label trial, 1748 subjects with inadequately controlled T2D after a 12-week run-in period on insulin glargine and metformin were randomised to 1:1 to receive either semaglutide once- weekly (0.5 mg or 1.0 mg) or insulin aspart three times daily. The included population had a mean diabetes duration of 13.4 years and a mean HbA1c of 8.6%, with a target HbA1c of 6.5 - 7.5%. Treatment with semaglutide resulted in reduction in HbA1c at week 52 ( - 1.5% for semaglutide vs. - 1.2% for insulin aspart). The number of severe hypoglycaemic episodes in both treatment arms was low (4 episodes with semaglutide vs. 7 episodes with insulin aspart). Mean baseline body weight decreased with semaglutide (-4.1 kg) and increased with insulin aspart (+2.8 kg) and the estimated treatment difference was - 6.99 kg (95%CI -7.41 to - 6.57) at week 52. |
| IA/0028 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/03/2022 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| PSUSA/10671 /202105   | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                | 13/01/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                           |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0021                | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                               | 11/11/2021   | 11/01/2022 | SmPC, Labelling and PL |                                                                                                                                                             |
| IB/0026/G             | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 22/11/2021   | n/a        |                        |                                                                                                                                                             |
| IB/0025               | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                     | 17/11/2021   | n/a        |                        |                                                                                                                                                             |
| PSUSA/10671 /202011   | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                | 08/07/2021   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                           |
| PSUSA/10671 /202005   | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                | 28/01/2021   | 22/03/2021 | SmPC and PL            | Please refer to Ozempic PSUSA-10671- 202005 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |

<div style=\"page-break-after: always\"></div>

| II/0019   | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/01/2021   | n/a        |             |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----|
| IB/0020/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished                                                                                                       | 09/12/2020   | n/a        |             |     |
| II/0014   | Update of sections 4.2 and 5.1 of the SmPC in order to include information on the use of semaglutide once weekly in combination with a SGLT-2 inhibitor, based on the final results from the SUSTAIN 9 study (study NN9535 -4269); a 30-weeks, randomised, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of semaglutide as add-on to treatment with an SGLT-2 inhibitor ± metformin or sulphonylurea in subjects with T2DM. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 03/12/2020   | 22/03/2021 | SmPC and PL | n/a |

<div style=\"page-break-after: always\"></div>

| IB/0018             | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS   | 15/10/2020   | n/a        |             |                                                                                                                                                             |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10671 /201911 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                            | 23/07/2020   | 30/09/2020 | SmPC and PL | Please refer to OZEMPIC PSUSA-10671- 201911 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IA/0016             | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits                                                            | 29/05/2020   | n/a        |             |                                                                                                                                                             |
| II/0011             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                | 14/05/2020   | n/a        |             |                                                                                                                                                             |
| IB/0015             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                               | 30/04/2020   | n/a        |             |                                                                                                                                                             |
| N/0012              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                     | 09/04/2020   | 30/09/2020 | PL          |                                                                                                                                                             |
| PSUSA/10671 /201905 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                            | 30/01/2020   | 27/03/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10671/201905.                  |
| IG/1092             | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                  | 12/07/2019   | n/a        |             |                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| PSUSA/10671 /201811   | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/06/2019   | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0008               | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                          | 11/04/2019   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0006               | Submission of an updated RMP version 3.1 in order to reflect that final protocols for Studies NN9535 - 4447 and NN9535 - 4352 have been provided (included as milestones under 'additional pharmacovigilance activities' in the RMP). Further the RMP is updated in line with the new template in accordance with Guideline on GVP Module V - Risk management systems (Rev 2). C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 11/04/2019   | n/a        |      | n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10671 /201805   | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/01/2019   | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0001               | Update of sections 4.8 and 5.1 of the SmPC in order to reflect the final results from the SUSTAIN 7 trial (NN9535 -4216), a 40-week open-label trial comparing the safety and efficacy of 0.5 mg of Ozempic to 0.75 mg of dulaglutide and 1 mg of Ozempic to 1.5 mg of dulaglutide in patients on metformin with type-2 diabetes.                                                                                                                                         | 18/10/2018   | 13/05/2019 | SmPC | The MAH submitted the final results from the SUSTAIN 7 trial (NN9535 -4216), a 40-week open-label trial conducted in 1,201 patients and comparing the safety and efficacy of 0.5 mg of Ozempic to 0.75 mg of dulaglutide and of 1 mg of Ozempic to 1.5 mg of dula glutide in patients on metformin with type-2 diabetes. Superiority of semaglutide treatment in reducing HbA1c levels from baseline to week 40 was demonstrated for semaglutide 0.5 mg versus |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                               |            |            |                        | dulaglutide 0.75 mg as well as for semaglutide 1.0 mg versus dulaglutide 1.5 mg. A weight loss of ≥5% and ≥10% was achieved for more subjects with Ozempic 0.5 mg compared with dulaglutide 0.75 mg and with Ozempic 1 mg compared with dulaglutide 1.5 mg. Section 5.1 of the SmPC has been updated accordingly. Sections 4.8 and 5.1 have also been updated to reflect an observed increase in heart rate in Ozempic-treated subjects with cardiovascular risk factors in the long-term trial, compared to data from the phase 3a trials. Section 5.1 was also updated to reflect data on the comparison against dulaglutide, Gastrointestinal disorders were the most frequently observed adverse events, occurring in similar proportions of patients receiving Ozempic 0.5 mg, Ozempic 1 mg or dulaglutide 1.5 mg; although fewer patients had gastrointestinal disorders with dulaglutide 0.75 mg.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0004   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                             | 30/08/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0002/G | This was an application for a group of variations. B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is an integrated part of the primary packaging B.IV.1.z - Change of a measuring or administration device - Other variation B.IV.1.z - Change of a measuring or administration device - Other variation | 31/05/2018 | 13/05/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|